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Objective: To investigate the efficacy of repetitive transcranial magnetic stimulation
(rTMS) combined with cognitive training for treatment of cognitive symptoms in patients
with Alzheimer’s disease (AD). A secondary objective was to analyze associations
between brain plasticity and cognitive effects of treatment.
Methods: In this randomized, sham-controlled, multicenter clinical trial, 34 patients
with AD were assigned to three experimental groups receiving 30 daily sessions of
combinatory intervention. Participants in the real/real group (n = 16) received 10 Hz
repetitive transcranial magnetic stimulation (rTMS) delivered separately to each of six
cortical regions, interleaved with computerized cognitive training. Participants in the
sham rTMS group (n = 18) received sham rTMS combined with either real (sham/real
group, n = 10) or sham (sham/sham group, n = 8) cognitive training. Effects of
treatment on neuropsychological (primary outcome) and neurophysiological function
were compared between the 3 treatment groups. These, as well as imaging measures
of brain atrophy, were compared at baseline to 14 healthy controls (HC).
Results: At baseline, patients with AD had worse cognition, cerebral atrophy, and TMS
measures of cortico-motor reactivity, excitability, and plasticity than HC. The real/real
group showed significant cognitive improvement compared to the sham/sham, but
not the real/sham group. TMS-induced plasticity at baseline was predictive of post-
intervention changes in cognition, and was modified across treatment, in association
with changes of cognition.
Frontiers in Aging Neuroscience | www.frontiersin.org 1 July 2020 | Volume 12 | Article 200
fnagi-12-00200 July 6, 2020 Time: 20:45 # 2
Brem et al. Combinatory Treatment in AD
Interpretation: Combined rTMS and cognitive training may improve the
cognitive status of AD patients, with TMS-induced cortical plasticity at baseline
serving as predictor of therapeutic outcome for this intervention, and potential
mechanism of action.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01504958.
Keywords: clinical trial, randomized controlled, Alzheimer’s disease, transcranial magnetic stimulation, cognitive
training, plasticity, combinatory intervention
INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenerative
disease (Alzheimer’s Association, 2012) with cognitive decline
significantly affecting quality of life (Alzheimer’s Association,
2012). Given that pharmacological agents (Ballard et al., 2011)
have limited efficacy and entail unfavorable side effects (Ryu
et al., 2005) there is a pressing need for non-pharmacological
interventions to complement current options. Importantly, AD is
associated with alterations in synaptic function and mechanisms
of neuroplasticity (Koch et al., 2012; Rossini et al., 2015),
which can be assessed indirectly using transcranial magnetic
stimulation (TMS). TMS is a non-invasive technique to generate
brief and relatively focal electric currents in the brain via
electromagnetic induction. When applied as single or paired
pulses to the motor cortex, it provides a diagnostic tool to
interrogate cortico-motor reactivity and inhibitory/excitatory
intracortical circuits, respectively. As a therapeutic tool, TMS is
applied in trains of pulses, termed repetitive TMS (rTMS) to
induce changes in excitability of the activated neural circuits
that outlast the period of stimulation. TMS can thus be used
to modulate activity in brain areas implicated in the cognitive
and behavioral dysfunctions of AD. Furthermore, over the
last 15 years, a low-intensity form of patterned rTMS, termed
intermittent theta-burst stimulation (iTBS), has emerged as a
means to induce NMDA receptor (NMDAR)-dependent long-
term potentiation (LTP)-like plasticity (Huang et al., 2005, 2007).
When applied over the motor cortex, the after-effects of iTBS
are measured as the change in the amplitude of motor-evoked
potentials (MEPs) elicited by suprathreshold single-pulse TMS,
i.e., the change in cortico-motor reactivity, which is thought to
reflect cortical plasticity (Pascual-Leone et al., 1994). The after-
effects of rTMS and TBS protocols are state-dependent (Silvanto
and Pascual-Leone, 2008) and mechanisms underlying rTMS-
mediated neuromodulation are similar to neuroplastic effects
involved in learning (Cooke and Bliss, 2006). Therefore, targeting
neural networks with rTMS while engaging them, for example
in cognitive exercises, has been suggested to lead to functional
improvements (Freitas et al., 2011) resulting from synergistic
effects if repeated in time.
Cognitive training interventions designed to attenuate
cognitive decline in dementia typically train basic functions with
simple tasks, tapping, for example, into non-verbal and verbal
memory, language, and visuo-spatial skills (Hill et al., 2017).
Cognitive interventions alone have yielded inconsistent results to
date (Clare et al., 2003; Hill et al., 2017; Kallio et al., 2017), while
rTMS alone yielded positive results in AD, in a few studies with
relatively small samples (Cotelli et al., 2011; Ahmed et al., 2012;
Haffen et al., 2012). The concomitant application of these two
approaches has shown therapeutic promise in a small industry-
sponsored open trial (Bentwich et al., 2011), and three follow-up
trials comparing the combined intervention with a control group
receiving sham rTMS and sham cognitive training (Rabey et al.,
2013; Lee et al., 2015; Rabey and Dobronevsky, 2016). A recent
review emphasizes the need for larger studies, and further
suggests investigation of treatment-related neurophysiological
markers (Buss et al., 2019). Our study builds on and extends
these preliminary studies in two important ways. First, we
included a control group of AD patients who received sham
rTMS with real cognitive training, in order to elucidate effects
of cognitive training alone. Furthermore, we aimed to provide
mechanistic insight into the intervention by characterizing
the neurophysiology of participants using TMS assessments of
cortical reactivity, inhibitory/excitatory intracortical circuits,
and plasticity, that were assessed longitudinally and also
compared at baseline to a group of healthy matched controls
(HC). Specifically, we hypothesized that such rTMS-cognitive
training-dependent modulation of plasticity is associated with
lasting changes in cognition. Moreover, we hypothesized that
cortical plasticity is reduced in patients with AD relative to
HC, as has been shown in previous studies (Koch et al., 2012;
Di Lorenzo et al., 2016) and is modulated by neuronavigated
rTMS to multiple brain regions interleaved with region-specific
cognitive training.
MATERIALS AND METHODS
Subjects
In this proof-of-principle, randomized, double-blind, sham-
controlled study we examined 35 patients diagnosed with
mild-moderate AD [DSM 5, NIA-AA (McKhann et al.,
1984) Figure 1A and Table 1). Patients were randomized
using concealed randomization practices (study-independent
researcher) and a 2:1:1 group distribution to one of three groups:
(1) real cognitive training combined with real rTMS (real/real:
n = 16), (2) sham cognitive training and sham stimulation
over the same brain regions (sham/sham: n = 8), or (3) real
cognitive training and sham rTMS (real/sham: n = 11) (see
Figure 1B for an overview of the study design). Except for
the technicians applying the intervention, all experimenters
and patients were blinded. Findings from two trials, one in
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FIGURE 1 | CONSORT flowchart: Enrollment and study design. (A) Flow diagram of the enrollment process and final study participants analyzed. (B) Schematic
representation of study design.
Boston (n = 21) and one in Rome (n = 13), were combined to
increase the sample size and reach more reliable conclusions.
The eligibility criteria were the following: subjects diagnosed
with mild to moderate Alzheimer’s disease according to DSM-
5 criteria and criteria established by the NIA-AA (McKhann
et al., 1984) for AD, at medium level of certainty according to
PET and/or MRI examination; age between 55 and 90 years;
written informed consent; MMSE between 18 and 24; normal
or corrected ability to see and hear; English (Boston) or
Italian (Rome) as primary language. The exclusion criteria were:
unstable/chronic medical conditions; major structural/vascular
abnormalities, agitation, psychiatric disorders, substance abuse,
other progressive neurological disorders different from diseases
causing cognitive impairment, or conditions considered a
potential hazard for the application of rTMS (Rossi et al., 2009).
Patients treated with cholinesterase inhibitors or ginkgo-biloba
were allowed to participate if the treatment had started at
least 3 months prior to screening and remain stable for the
duration of the study. One participant from the real/sham group
was excluded due to the incidental finding of a brain lesion.
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TABLE 1 | Demographic, neuropsychological, morphometric, and neurophysiologic features of study participants (before intervention).
AD group
(n = 21, B)
(n = 13, R)
Healthy controls
(n = 13, B)
p-value Real/Real
intervention (n = 16)
Sham/Sham
intervention (n = 8)
Real/Sham
intervention (n = 10)
p-value
Age (years)* 68.79 ± 7.17 66.00 ± 7.19 0.317 69.25 ± 6.80 67.50 ± 10.27 69.10 ± 5.24 0.710
Gender* 20 Female, 14 Male 7 Female, 6 Male 0.520 12 Female, 4 Male 3 Female, 5 Male 5 Female, 5 Male 0.169
Education (years)* 14.91 ± 4.72 15.62 ± 2.22 0.745 14.25 ± 4.64 17.50 ± 4.00 13.90 ± 5.07 0.064
Medication* 3 MEM
7 COM,
6 AChEI
0 None
0 MEM
2 COM
5 AChEI
1 None
2 MEM
3 COM
1 AChEI
4 None
0.053
SBD left IPL (mm) 24.60 ± 9.78 17.15 ± 2.87 0.008 23.50 ± 6.66 26.13 ± 13.49 24.98 ± 12.02 0.961
SBD mean (mm) 18.96 ± 3.57 16.27 ± 2.29 0.005 18.36 ± 3.01 20.38 ± 4.17 18.46 ± 4.17 0.555
MMSE* 21.71 ± 2.47 29.46 ± 0.88 <0.000 21.19 ± 2.69 20.88 ± 2.95 22.00 ± 1.83 0.662
ADAS-Cog* 23.76 ± 9.90 4.25 ± 1.97 <0.001 23.00 ± 9.92 23.61 ± 11.29 25.10 ± 9.67 0.670
ADCS-ADL* 56.77 ± 19.69 74.31 ± 3.45 0.002 60.93 ± 15.96 54.67 ± 17.99 51.80 ± 25.64 0.473
GDS 2.43 ± 2.34 0.69 ± 1.11 0.020 2.00 ± 2.00 2.67 ± 3.08 3.00 ± 2.35 0.576
rMT 42.33 ± 10.57 46.82 ± 12.33 0.326 44.12 ± 7.02 42.44 ± 14.64 38.60 ± 12.40 0.381
aMT 42.54 ± 9.99 46.42 ± 8.74 0.309 45.53 ± 5.70 43.00 ± 12.74 36.00 ± 12.10 0.179
SICI 0.66 ± 0.39 0.34 ± 0.23 0.025 0.63 ± 0.52 0.69 ± 0.20 0.70 ± 0.29 0.784
ICF 1.43 ± 0.85 1.43 ± 0.56 0.611 1.23 ± 0.73 2.10 ± 0.97 0.94 ± 0.26 0.081
LICI 0.59 ± 0.79 0.04 ± 0.06 0.004 0.41 ± 0.58 1.06 ± 1.13 0.34 ± 0.43 0.289
MC reactivity 1246 ± 1010 1184 ± 620 0.727 1222 ± 1182 814 ± 473 1815 ± 995 0.203
MC max. plasticity 1.50 ± 0.92 1.87 ± 0.65 0.020 1.53 ± 1.34 1.33 ± 0.15 1.66 ± 0.34 0.147
MC mean plasticity 1.09 ± 0.49 1.45 ± 0.60 0.040 1.04 ± 0.63 0.99 ± 0.12 1.32 ± 0.44 0.412
*These parameters include the Rome sample (n = 34). AChEI, acetylcholinesterase inhibitors; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Cooperative
Study–Activities of Daily Living Inventory; B, Boston sample (n = 21); COM, combination therapy with AChEI and memantine; GDS, Geriatric Depression Scale; ICF, intracortical facilitation; IPL, inferior parietal lobule;
LICI, long-interval intracortical inhibition; MC, motor cortex; MEM, memantine; MMSE, Mini-Mental State Examination; R, Rome sample (n = 13); rMT/aMT, resting/active motor threshold; SBD, Scalp-brain distance;
SICI, short-interval intracortical inhibition; T5/T10, Time-points at 5 and 10 min post intermittent Theta Burst Stimulation. Group values are presented as mean ± standard deviation (SD), p-values are two-tailed. Bold
font indicates significant p-values.
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AD patients had a score of 1 (n = 30) or 2 (n = 4 participants
studied in Rome) on the Clinical Dementia Rating scale (CDR),
and a Mini-Mental State Examination (MMSE) score between 18
and 24, and 29 of them were medicated (Table 1). We also studied
14 age-matched healthy controls (HC), who underwent the same
baseline evaluation as the AD participants in Boston. One HC
was excluded as a statistical outlier in several measures. All HC
had normal physical, neurological and cognitive exams (CDR = 0
and MMSE score ≥ 28).
Neurophysiological assessment of cortical function was
completed in the participants studied in Boston (real/real: n = 10;
combined sham groups: n = 11). Two participants in the sham
group did not complete post-intervention measures (due to
their distance from the testing site). Interventions took place at
the Berenson-Allen Center for Noninvasive Brain Stimulation
and the Harvard-Thorndike Clinical Research Center, Beth
Israel Deaconess Medical Center, Boston, United States or at
the Polyclinic A. Gemelli, Rome, Italy. The local Institutional
Review Boards at both institutions (Beth Israel Deaconess
Medical Center and Polyclinic A. Gemelli Foundation-IRCCS)
approved the study. Participants and their legally authorized
representatives (if appropriate) gave written informed consent
prior to study onset. AD data from the Boston study originate
from the trial registered at ClinicalTrials.gov NCT01504958.
Cognitive and Behavioral Measures
Cognitive and behavioral functions were assessed within 2 weeks
before and 1 week after the therapeutic intervention using
tests and inventories drawn from the National Alzheimer’s
Coordinating Center – Uniform Data Set (v1) (Beekly et al.,
2007). The cognitive subscale of the Alzheimer’s Disease
Assessment Scale (ADAS-Cog) was defined as the primary
outcome and re-assessed at 1-month follow-up in the Boston
and 6 weeks in the Rome sample. The Geriatric Depression
Scale (GDS) and the CDR were evaluated at baseline, and
the Clinical Global Impression of Change (ADCS-CGIC)
was administered after the intervention. To minimize
practice/learning effects, alternate forms were used and
counterbalanced whenever possible. The ADAS-Cog and
ADCS-CGIC and CDR were administered by board-certified
neuropsychologists/neurologists, while all other measures,
including the Activities of Daily Living (ADCS-ADL) inventory
were administered by trained psychometrists. The same
experimenter administered the neuropsychological tests at all
time points. Participants studied in Rome did not undergo
assessment with ADCS-CGIC or GDS.
Motor Thresholds, Brain Reactivity, and
Plasticity
Resting and active motor thresholds (rMT, aMT), motor
cortical reactivity, inhibitory/excitatory intracortical circuits,
and plasticity were evaluated with TMS combined with
electromyography (EMG), at baseline and after the therapeutic
intervention (Figure 1B). The eXimia Navigated Brain
Stimulation (NBS) system 4 (Nexstim, Finland) was used
for single- and paired-pulse stimulation using a handheld
figure-of-eight focal biphasic and monophasic coil, respectively.
The coils were held over the left motor cortex to elicit motor
responses in the contralateral first dorsal interosseous (FDI)
muscle. Intensities during assessment of the rMT and aMT
were expressed as a percentage of the maximum output of the
stimulator. The stimulation was performed positioning the
virtual cathode of the coil centered over the site of the scalp to
be stimulated and the holder oriented at a 45◦ angle with respect
to the approximate direction of the central sulcus (current
flow in postero-anterior direction). The rMT was defined as
the minimum intensity of the magnetic field able to generate
a motor evoked potential (MEP) of 50 µV in approximately
50% of 10 consecutive stimuli, i.e., generating 5 MEPs out of
10 trials (Rossini et al., 1994, 2015). The aMT was defined as
the minimum stimulus intensity that produced a liminal MEP
(about 200 µV in 50% of 10 trials) during isometric contraction
of the tested muscle.
After assessing rMT and aMT, MEP amplitudes were
measured from the right FDI muscle using 30 × 22 mm gel
surface electrodes (Ambu, United Kingdom; active over muscle
belly, reference over proximal interphalangeal joint of the index
finger, ground on the ulnar styloid process). Stimulation intensity
for all single-pulse TMS trials was set at 120% of rMT. For
paired-pulse TMS, test pulse intensity was set at 120% rMT,
while the conditioning pulse intensity and inter-pulse interval
(IPI) determined the type of measurement: 80% rMT with a
3-ms IPI to assess short-interval intracortical inhibition (SICI),
80% rMT with a 12-ms IPI to evaluate intracortical facilitation
(ICF), and 120% rMT with an IPI of 100 ms to measure
long-interval intracortical inhibition (LICI). Intermittent TBS
(iTBS) was applied at 80% of aMT. Paired pulse measures were
assessed in separate sets (50 pulse pairs with a jittered inter-trial
interval of 5–6 s) and expressed as a ratio of the test-MEP to
a block of 50 unconditioned pulses. Baseline cortical reactivity
(three sets of 30 single TMS pulses) was followed by a 600-
pulse regimen of iTBS (20 two-second trains of 50 Hz burst-
triplets repeated every 200 ms; MagPro X100, MagVenture A/S,
Denmark). Cortical reactivity was reassessed at 5, 10, 20, and
30 min post-iTBS in sets of 30 single TMS pulses. Cortico-motor
plasticity was expressed as the percent change from baseline in
cortical reactivity. Maximum brain plasticity was defined as the
largest of these measures taken at any of the time-points assessed.
Intervention: Cognitive Training and
rTMS
Intervention consisted of daily (monday-to-friday) 1-h sessions
of combined cognitive training (real or sham) synchronized with
rTMS (real or sham) for 6 weeks (total of 30 sessions) using
NeuroAD (Neuronix Medical, Yoqneam, Israel). The NeuroAD
system combines brief trains of 10 Hz rTMS targeting brain
regions known to be affected in AD (i.e., frontal, temporal, and
parietal regions) (Mattson, 2004) interleaved with an adaptive
computerized cognitive training program designed to engage
the regions targeted by rTMS (Table 2A). Trains of rTMS (20
trains of 2 s, 10 Hz per region per day at 120% rMT) were
applied using a handheld figure-of-eight focal coil (SuperRapid
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TABLE 2A | Cognitive training and morphometric and technical parameters of interest.
Brain Region L IFG L STG R DLPFC L DLPFC R IPL L IPL
Cognitive tasks Sentence
similarities,
differentiate
right/wrong
sentences
Differentiate
words/pseudo
words, assign
pictures to
categories
Action naming,
word recall
Remember
color/location of
rectangles, word
recall
Identify red/blue
rectangles
Identify letters
B/T/M in a cluster
of letters
Task examples
(A) Cognitive training tasks were designed to train the following functions: syntax, grammar, lexical meaning, categorization, action naming, object naming, spatial memory,
and spatial attention. Cognitive tasks were associated with the stimulation of specific brain areas: L IFG (Broca’s area): determine whether sentences are grammatically
correct; L STG (Wernicke’s area): differentiate between words and pseudo words, or to assign pictures to one of two categories; R DLPFC: match written descriptions
with pictures; L DLPFC: remember locations and colors of rectangles; R IPL: identify red or blue vertical rectangles within an array of stimuli; L IPL: identify a particular
letter in a cluster of random letters. Notably, stimulating several brain areas per session might in turn activate remotely associated hubs of the same networks, possibly
leading to a more extensive modulation. For each cognitive task, the difficulty level was adjusted individually and increased following successful completion of a previous
level (≥80% correct answers). An increase in difficulty level was either achieved by increasing stimulus-response time, or by increasing the number of displayed target
and distracter stimuli. (B) Difficulty levels (12 per task) achieved by the real/real and the real/sham group, scalp-brain distances, and stimulation intensity applied per
TMS-targeted region. Values are presented as mean standard deviation (SD). (C) Correlations between maximum difficulty level achieved during cognitive training tasks
per TMS-targeted region with stimulation intensity (real/real group) and with scalp-to-brain distance (real/real and real/sham group). Neurophysiological measures include
the Boston sample only (n = 21). L IFG, left inferior frontal gyrus; L STG, left superior temporal gyrus; R and L DLPFC, right and left dorsolateral prefrontal cortex; R and L
IPL, right and left inferior parietal lobule; SDB, scalp-to-brain distance; t, Kendall’s tau. P-values are one-tailed.
TABLE 2B |
Brain Region L IFG L STG R DLPFC L DLPFC R IPL L IPL Average
Difficulty level real/real 6.90 ± 2.74 7.40 ± 2.16 6.70 ± 3.06 5.35 ± 3.38 7.90 ± 0.99 6.10 ± 2.81 6.73 ± 1.90
Difficulty level real/sham 5.25 ± 1.56 5.30 ± 2.49 6.40 ± 3.21 5.00 ± 3.45 7.00 ± 3.46 6.20 ± 3.21 5.86 ± 2.62
Scalp-to-brain distance 18.21 ± 5.64 13.29 ± 2.18 21.04 ± 9.50 14.43 ± 3.28 21.78 ± 6.82 23.50 ± 6.66 18.36 ± 3.01
Stimulation intensity (training) 63.92 ± 12.97 63.92 ± 12.97 64.73 ± 14.46 63.92 ± 12.97 64.73 ± 14.46 63.92 ± 12.97 64.19 ± 13.42
Values are presented as mean ± standard deviation (SD).
TABLE 2C |
Brain Region L IFG L STG R DLPFC L DLPFC R IPL L IPL Average
τ (difficulty level, stimulation intensity) real/real 0.25 −0.75 0.454 0.66 0.48 0.57 0.54
p-value 0.486 0.836 0.188 0.040 0.161 0.085 0.111
τ (difficulty level, SBD) real/real and real/sham 0.13 −0.46 −0.06 −0.18 −0.53 −0.71 −0.40
p value 0.658 0.087 0.828 0.515 0.040 0.003 0.136
L IFG, left inferior frontal gyrus; L STG, left superior temporal gyrus; R and L DLPFC, right and left dorsolateral prefrontal cortex; R and L IPL, right and left inferior parietal
lobule; SDB, scalp-to-brain distance; τ, Kendall’s tau. P-values are one-tailed. Bold font indicates significant p-values and correlation coefficients.
stimulator, Magstim Co. Ltd., Whitland, United Kingdom)
and were each followed by a cognitive task presented on a
touch-screen monitor (20–40 s). During each session, focal
stimulation was applied to 3 of 6 predefined brain regions
in a pseudo-randomized sequence, without counterbalancing
the stimulation sequence between patients. This strategy was
devised to ensure the same amount of stimulation per target-
region, with each region stimulated 15 times over the course
of the intervention. Though rTMS was performed using a focal
coil to only one region at a time, the combined effects of
stimulating multiple regions over the course of each session could
lead to similar effects to those of multifocal stimulation (i.e.,
concurrent stimulation to several brain regions). The frameless
stereotaxic neuronavigation system Brainsight (Rogue Research,
Inc., Canada) was used to individually select the targets, guide
coil placement, and measure scalp-brain distance, as a surrogate
measure of cortical atrophy. The following predefined cortical
regions were individually targeted by transforming published
group average coordinates into individual MRI space: right/left
DLPFC (R/L DLPFC) (Rusjan et al., 2010), right/left IPL (R/L
IPL) (Sajonz et al., 2010), Wernicke area in the left superior
temporal gyrus (L STG) (Price et al., 2003) and Broca’s area in
the left inferior frontal gyrus (L IFG) (Rogalsky et al., 2008).
Sham rTMS was delivered with a sham TMS coil (Magstim)
that imitated auditory and somatosensory sensations. Regarding
cognitive training, for each task, difficulty levels were adapted for
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each patient, according to performance (Table 2B). The sham
cognitive training consisted of a picture preference task using
the same stimuli as in the real cognitive training. Participants
had to indicate for each picture whether they find it “nice” or
“not nice.” The presentation of cognitive stimuli and rTMS were
synchronized via the NeuroAD system.
Scalp-Brain Distance Measurements
Scalp-brain distance was defined as the distance between the
outer edge of the cortical surface and the outer edge of the scalp
and was measured for each target in the plane perpendicular
to the scalp tangent (i.e., orthogonal to the plane of the TMS
coil) on each individual’s brain MRI for the six stimulated
regions and the left motor cortex (site of TMS measures)
using Brainsight (Rogue Research Inc., Canada). These measures
served as a surrogate indicator of regional brain atrophy
(Rusjan et al., 2010) (Table 2B).
Data Analysis
Data were analyzed using SPSS Statistics 21.0 (SPSS Inc., Chicago,
IL, United States) and SAS (version 9.3, SAS Institute, Cary,
NC, United States). Significance was set using a 95% confidence
interval (α = 0.05).
Individual MEP amplitudes that were greater than 1.5
standard deviations from the mean were excluded. Baseline
motor cortical reactivity was defined as the mean MEP amplitude
across all 90 trials. To assess plastic changes after iTBS, MEPs
from each post-iTBS time point were averaged and divided by
baseline. Additionally, the achieved degree of difficulty during
cognitive training was assessed for its relationship with atrophy
and stimulation intensity.
Group and post hoc analyses were calculated with non-
parametric Kruskal–Wallis and Mann–Whitney U tests,
respectively. Correlations [bootstrapped with 10,000 resamples
with bias-corrected confidence intervals] were calculated using
Pearson’s r tests for whole group analysis and Kendall’s tau tests
for subgroup analyses. After finding no difference between the
real/sham and sham/sham groups (see section “Results”) both
were combined into a single sham rTMS group to increase power.
Change in ADAS-Cog (ratio post/pre) was defined as primary
outcome and the effect of depression on ADAS-Cog outcome was
assessed with a mediation analysis. The difference in ADAS-Cog
in the real/real group was tested with a two-sided paired t-test
(pre vs. post-treatment and pre-treatment vs. follow-up).
Multivariable linear models were built to test either
associations between ADAS-Cog and other clinical,
demographic, and physiological variables at baseline, or the
prediction of the clinical response by said variables, and/or
intervention parameters (real vs. sham rTMS and real vs. sham
cognitive stimulation). Longitudinal mixed effects models were
built to test associations between ADAS-Cog and physiological
variables across repeated assessment moments, when adjusting
for baseline clinical and demographic variables. Initial models
were built according to prior knowledge, and sequential
regression models used to test the relevance of additional
variables of interest. Data transformations and polynomial
models were used to test the better alternative to fit continuous
predictors, and relevant interaction terms, namely interactions
with active rTMS intervention, were tested. Model assumptions
were tested by analyses of residuals, and influence diagnostics
were conducted using Cook’s distance.
RESULTS
Baseline Comparisons
See Table 1 for an overview of baseline comparisons between AD
and HC and across the AD intervention groups. The AD groups
did not differ in any of the baseline measures. AD and HC did
not differ in age, education, gender, and TMS-measures of rMT,
aMT and motor-cortical reactivity. However, depression scores as
assessed with the GDS were significantly higher in AD (U = 71.5,
z = −2.41, p = 0.020, r = −0.41), as was brain atrophy (scalp-
brain distance) for the left IPL (U = 63.0, z = −2.61, p = 0.008,
r = −0.45) and averaged across seven brain regions (U = 58.5,
z = −2.77, p = 0.005, r = −0.47) (Tables 1, 2B).
Plasticity indices measured up to 30 min after iTBS were
significantly different between AD patients and HC at T5
(U = 183, z = 2.13, p = 0.033, r = 0.37), T10 (U = 179, z = 1.98,
p = 0.048, r = 0.35), and averaged over T5 to T30 (U = 181,
z = 2.06, p = 0.040, r = 0.36) (Figure 2A). Furthermore, the
maximum plasticity change (U = 187.5, z = 2.302, p = 0.020,
r = 0.40) was significantly smaller in AD. ICF was similar in AD
and HC, while SICI and LICI were significantly reduced in AD
(SICI: U = 56, z = −2.23, p = 0.025, r = −0.40; LICI: U = 42,
z = −2.81, p = 0.005, r = −0.50) (Figure 2B).
After adjusting for a 5% False Discovery Rate (FDR), non-
significant trends were observed for plasticity indices at T5
and T10, as well as overall and maximum plasticity change
(p < 0.1), while differences in SICI and LICI remained significant
(p < 0.05). Furthermore, atrophy of the left IPL and average
atrophy remained significantly larger in AD (p < 0.05).
Intervention Effects in Alzheimer Disease
Patients
The largest score change in ADAS-Cog within 4–6 weeks after
the end of intervention was significantly different between groups
(H[2] = 10.16, p = 0.006) (Figure 2C). Post hoc tests revealed
a significantly higher improvement in the real/real group as
compared to the sham/sham (U = 115, z = 3.13, p = 0.001,
r = 0.64) but not the real/sham group (U = 110, z = 1.56, p = 0.121,
r = 0.31). Immediately after the intervention, the real/real
group improved their cognitive score on average by 2.18(±3.70)
points, while the real/sham group improved by 0.4(±4.14) points
and the sham/sham group showed a decline of 0.49(±2.48)
points. During the following 4–6 weeks post-intervention, the
real/real group continued to improve on average by an additional
1.69(±4.07) points, that is, at the end of the follow-up period
the real/real group improved on average by 3.87(±4.54) points
from baseline (Figure 2D). Notably, the immediate change from
pre to post-treatment in the real/real group reached statistically
significant levels (t(15) = 2.408, p = 0.029, CI 95% [0.253, 4.16]) as
well as the change from pre to follow-up (t(15) = 3.413, p = 0.004
CI 95% [1.45, 6.29]). Neither of the sham groups (real/sham and
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FIGURE 2 | (A) Plasticity change at T5, T10, and on average at T5–30 (T mean) expressed as the mean ratios of single-pulse TMS-measured MEP amplitudes
pre-post iTBS before the intervention. (B) Paired-pulse TMS-measures of short-interval intracortical inhibition (SICI), intracortical facilitation (ICF), and long-interval
intracortical inhibition (LICI) in AD (before intervention) and HC. (C) (including Italian sample): Best individual score change (ratio post/pre) in ADAS-Cog after
real/real (light grey), sham/sham (medium grey), and after combined real cognitive training with sham rTMS (black). (D) Average ADAS-Cog score at pre, post and
follow-up in the three treatment groups. (E) Average ADCS-CGIC scores. A score of 4 (dotted line) is equivalent to no change from pre- to post-intervention, scores
< 4 indicate improvement, scores > 4 indicate decline. Indicated values correspond to mean ± standard error (SE).
sham/sham) showed a significant cognitive change from pre to
post (Supplementary Table S2). Importantly, two-thirds of the
patients in the real group continued to improve in ADAS-Cog
even after the end of intervention. Comparing across groups, a
marginally significant difference was observed in ADCS-CGIC
(real/real: 3.25 ± 0.72, sham/sham: 4.08 ± 1.02, real/sham:
4.40 ± 0.89; H[2] = 5.950, p = 0.051). We thus decided to explore
post-hoc results and found a significantly larger improvement
for the real/real as compared to the real/sham group (U = 42,
z = 2.21, p = 0.04, r = 0.57) (Figure 2E), while the other group
comparisons did not reach significance. The score change in
ADCS-ADL immediately after the end of the intervention was
significantly different between groups (H[2] = 6.95, p = 0.031).
Post hoc tests showed that the real/real group (U = 18, z = −2.12,
p = 0.036, r = −0.46) as well as the real/sham group (U = 53,
z = 2.5, p = 0.011, r = 0.63) showed a significantly better outcome
than the sham/sham group. The real/real and real/sham groups
did not differ significantly in ADL outcome (U = 89, z = 0.79,
p = 0.461, r = 0.16).
As hypothesized, the two sham groups did not differ
significantly with regard to their largest ADAS-Cog score change
(U = 23, z = −1.56, p = 0.122, r = 0.34) and their outcomes
in ADCS-CGIC (U = 19, z = 0.76, p = 0.537, r = 0.23). We
therefore followed our strategy in accordance with the 2:1:1 group
randomization and further compared the real/real group (n = 16)
with the combined sham groups (n = 18) in order to assess
rTMS-specific intervention effects and increase statistical power.
In these analyses the difference for ADAS-Cog score change
remained significant (U = 225, z = 2.78, p = 0.004, r = 0.48)
and the change in ADCS-CGIC (sham n = 11, real/real n = 10)
became significant (U = 87, z = 2.35, p = 0.024, r = 0.51).
Moreover, the change in ADAS-Cog was correlated with clinical
changes as indicated by CGIC (r = 0.473, p = 0.031, 95% CI 0.08
to 0.75). Furthermore, a mediation analysis with bootstrapping
(10,000 samples, Preacher and Hayes, 2008), to examine the effect
of depression on intervention outcome, showed that depression
scores did not account for the variance in ADAS-Cog (R2 = 0.15,
F(2,18) = 1.625, p = 0.225; 95% bias corrected confidence interval
for the mediating variable: [−0.007 to 0.037]). No major side
effects were reported in any participants.
Association of Cognitive With
Physiological and Other Measures
At baseline, ADAS-Cog (lower values indicate better cognitive
function) was significantly correlated with rMT (r = −0.44,
p = 0.009, 95% CI −0.64 to −0.20), SICI (r = 0.564, p = 0.001, 95%
CI 0.21 to 0.77) and marginally with LICI (r = 0.304, p = 0.096,
95% CI 0.03 to 0.71), as well as atrophy in the left IPL (r = 0.42,
p = 0.013, 95% CI 0.09 to 0.70), and mean atrophy (r = 0.37,
p = 0.033, 95% CI 0.00 to 0.68). Atrophy in the motor cortex was
positively correlated with rMT (r = 0.389, p = 0.023) across all
participants. Cortical reactivity and plasticity were not associated
with cortico-motor atrophy (ps > 0.05). The maximum difficulty
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level reached in region-specific tasks was significantly correlated
with absolute TMS intensity for the left DLPFC (r = 0.66, p = 0.04)
in the real/real group and with atrophy in the left (r = −0.707,
p = 0.003) and the right IPL (r = −0.534, p = 0.04) (Table 2C).
In multivariable linear regression analyses with data from
all participants at baseline, the association of ADAS-Cog with
rMT and SICI was confirmed, and found also for aMT,
mean plasticity indices averaged over T5–T30, maximum
plasticity, and LICI (Table 3 and Figure 3). None of these
associations were confounded by mean atrophy. However,
the associations between baseline ADAS-Cog and plasticity
measures, as well as LICI, were no longer significant when
adjusting for diagnosis. In additional linear regression analyses
of ADAS-Cog ratio (post-intervention/baseline) as a measure
of response to treatment in patients with AD, when adjusting
for rTMS intervention, a significant predictor of response in
all models, age, education, gender, and cognitive training were
not significant predictors of response. However, mean atrophy
and atrophy over the left DLPFC, but not other cortical areas,
were found to be significant predictors of response (Table 3).
Importantly, in similar rTMS adjusted analyses, MEP amplitude,
as well as plasticity at T5 and T10, mean plasticity from T5 to
T30 and maximum plasticity, were all found to be significant
predictors of response (Table 3 and Figure 3). Interaction
TABLE 3 | Parameter estimates and model fit statistics for multivariable linear models testing associations between TMS-driven measures of cortico-motor reactivity
evaluated at baseline, and cognitive function (ADAS-Cog) also measured at baseline, or clinical response (ADAS-Cog ratio) in the sample from Boston (n = 21).
Linear Models
Dependent variable Baseline ADAS-Cog (AD and HC) ADAS-Cog ratio
(post-intervention/baseline; AD only)
Base model Independent variables Beta ± SE p R2 Beta ± SE p R2
Age (years) 0.3 ± 0.3 0.3 0.09
Education (years) 0.3 ± 0.7 0.6
Mean SBD 1.3 ± 0.6 0.04
rTMS −0.25 ± 0.06 <0.001 0.42
Single clinical or demographic
variables added to base model
Diagnosis −18 ± 3.6 <0.0001 0.5
Cognitive stimulation −0.1 ± 0.08 0.1 0.47
Age (years) −2.4*10−4 ± 4.6*10−3 0.96 0.39
Gender (male) −0.02 ± 0.07 0.8 0.39
Education (years) 6.9*10−3 ± 8.8*10−3 0.4 0.41
Mean SBD −0.02 ± 8.7*10−3a 0.02 0.54
Single structural variables
(scalp-brain distance) added to
base model
Left DLPFC −0.02 ± 0.01a 0.03 0.51
Right DLPFC −5.2*10−3 ± 4.3*10−3 0.2 0.44
Left IFG −3.2*10−3 ± 5.5*10−3 0.6 0.4
Left IPL −3.6*10−4 ± 3.4*10−3 0.9 0.39
Right IPL −2,6*10−3 ± 4*10−3 0.5 0.41
MC −6.1*10−3 ± 0.01 0.6 0.4
Left STG −4.6*10−3 ± 5.3*10−3 0.4 0.42
Mean distance (7 areas) −0.02 ± 8.7*10−3a 0.02 0.54
Single physiological variables
added to base model
rMT −0.7 ± 0.2 <0.001 0.42 1.8*10−3 ± 3.2*10−3 0.6 0.4
aMT −0.7 ± 0.2 0.001 0.35 2.4*10−3 ± 3.4*10−3 0.5 0.41
MEP amplitude 1.9*10−3 ± 2.5*10−3 0.4 0.08 −1*10−4 ± 4*10−5a 0.02 0.56
Plasticity T5 −4.3 ± 3.9 0.3 0.08 −0.2 ± 0.1a,b <0.05 0.5
Plasticity T10 −8.7 ± 4.3a 0.06 0.25 −0.2 ± 0.08a 0.02 0.56
Mean Plasticity T5-T30 −8.9 ± 4.3a <0.05 0.26 −0.3 ± 0.1a 0.02 0.54
Maximum plasticity T5-T30 −9.9 ± 4.1a 0.02 0.31 −0.2 ± 0.09a,b <0.05 0.52
SICI 19.5 ± 5.1 <0.001 0.39 0.08 ± 0.09 0.4 0.42
ICF −1.9 ± 3.2 0.6 0.06 0.02 ± 0.04 0.7 0.39
LICI 12.2 ± 4.4a 0.01 0.34 0.05 ± 0.04 0.2 0.43
aOne or more subjects were not included in this model due to being influential observations according to Cook’s distance analysis. bBecomes only marginally significant
(0.05 < p < 0.08) when adjusted for mean scalp-brain distance. ADAS-Cog, cognitive subscale of the Alzheimer’s Disease Assessment Scale; ICF, intracortical facilitation;
LICI, long-interval intracortical inhibition; MEP, motor evoked potential; rMT/aMT, resting/active motor threshold; rTMS, repetitive transcranial magnetic stimulation; SBD,
Scalp-brain distance; SICI, short-interval intracortical inhibition; T5/T10/T30, Time-points at 5 10 and 30 min post intermittent Theta Burst Stimulation. Bold font indicates
significant values.
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FIGURE 3 | Relationship between TMS-driven measures and cognitive function (ADAS-Cog). Relationship at baseline (A–D) in AD and HC, or clinical response over
time (ADAS-Cog ratio) in AD patients (E–H) treated with real or sham rTMS. Cortico-motor plasticity was expressed as the change of cortical reactivity from baseline
to post-iTBS. Circles reflect data for individuals and lines are unadjusted regression lines for the specified groups. When adjusting for age, education and mean
atrophy, significant associations were found between baseline ADAS-Cog and resting motor threshold [rMT – (A)], short-interval intracortical inhibition [SICI – (B)],
long-interval intracortical inhibition [LICI – (C)] and mean plasticity from 5 to 30 min post-iTBS (D). However, in models adjusting for rTMS intervention (real vs. sham),
mean plasticity (H), but not rMT (E), SICI (F), and LICI (G) was found to be a significant predictor of response.
terms with rTMS were not significant and none of these
associations were confounded by cognitive stimulation. However,
plasticity at T5 and maximum plasticity became only marginally
significant predictors of clinical response when adjusting for
mean atrophy. The effects for the remaining predictors were not
significantly affected.
Even though change in neurophysiological parameters
exploring plasticity from pre to post-treatment did not
differ significantly between groups (H[2] = 0.464, p = 0.793)
(Supplementary Table S1), longitudinal regression models
were built to test physiological and other factors associated to
ADAS-Cog across intervention. These multivariable analyses
were adjusted for rTMS, that was again a significant parameter
in the models. In separate rTMS-adjusted models, age, gender,
education, cognitive stimulation and mean atrophy were not
associated to ADAS-Cog, and the latter two variables were
also not confounders in any of the subsequent models. As
found at baseline, rMT and aMT were significantly associated
to ADAS-Cog, but the associations with SICI, LICI, and T5
and T10 plasticity measures were no longer significant in
these longitudinal analyses. However, the association between
ADAS-Cog and both mean and maximum plasticity from T5 to
T30 remained significant. Importantly, these were also the only
instances where an interaction term between the physiological
measure and rTMS was also significant, showing not only that
these associations between cognition and physiology persist
across intervention, but also that they were modulated by active
rTMS treatment (Table 4).
DISCUSSION
The primary aim of the present study was to assess the efficacy
of rTMS combined with cognitive training for the treatment of
cognitive symptoms in AD patients. Furthermore, we aimed to
analyze if cortical plasticity was different in patients with AD
versus HC as shown in previous studies, whether its modulation
by the combined rTMS-training intervention was possible, and
whether it might be associated with changes in cognitive function.
For the primary aim, in order to reach a suitable sample size,
findings from two parallel trials utilizing the same recruitment
criteria, interventions, and cognitive assessments (Boston and
Rome) were combined.
Baseline Measures
At baseline, we found no significant difference in rMT and
aMT between patients with AD and HC. However, both were
robust indicators of severity of cognitive dysfunction, even when
controlling for brain atrophy. Cortico-motor plasticity revealed
significant differences between AD patients and HC, as could
be expected from findings of a positive correlation between
amyloid-β cerebrospinal fluid levels and long-term potentiation
(LTP)-like effects induced by iTBS (Mori et al., 2011). Another
study (Koch et al., 2012) showed significant differences in brain
plasticity between AD and HC at several time-points between 11
and 25 min after iTBS. We found significant differences for T5,
T10, average plasticity (T5–30), and for maximum iTBS-induced
plasticity, as well as significant linear associations between all
of these plasticity measures and ADAS-Cog at baseline, when
adjusting for several demographic and clinical factors, as well
as atrophy. Change in neurophysiological parameters exploring
plasticity from pre to post-treatment did not differ significantly
between AD groups. The differential time-course of post-iTBS
plasticity could be related to the fact that our patients were mostly
medicated, while Koch et al. (2012) investigated medication-
naïve patients. Huang et al. (2007) found that memantine
significantly impacts measures of TBS-induced plasticity in
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TABLE 4 | Parameter estimates and model fit statistics for multivariable mixed effects longitudinal models testing associations between TMS-driven measures of
corticomotor reactivity and cognitive function (ADAS-Cog), measured across time (pre and post-treatment), in the sample from Boston (n = 21).
Longitudinal Mixed Effects Models
Dependent variable: ADAS-Cog (AD only)
Independent variables Beta ± SE p
Base model rTMS −10.5 ± 3.8 0.006
Time (pre- vs. post treatment) −2.8 ± 0.9 0.002
Single clinical or demographic variables added to base model Cognitive stimulation −2.5 ± 5.4 0.6
Age (years) −0.07 ± 0.3 0.8
Gender (male) 4.8 ± 4 0.2
Education (years) 0.1 ± 0.5 0.9
Mean scalp-brain distance −0.3 ± 0.6 0.5
Single physiological variables added to base model rMT −0.5 ± 0.2 0.004
aMT aMT 1.9 ± 0.9 <0.05
aMT2 −0.02 ± 0.01 0.03
MEP amplitude 4.7*10−4 ± 6.4*10−4 0.5
Plasticity T5 1.5 ± 1.2 0.2
Plasticity T10 −0.4 ± 1.3 0.7
Mean Plasticity T5–T30 MeanT5-T30 5.2 ± 2.2 0.02
MeanT5-T30*rTMS −6 ± 2.6 0.02
Maximum Plasticity T5–T30 MaxT5-T30 4.9 ± 1.7 0.005
MaxT5-T30*rTMS −5.2 ± 1.9 0.005
SICIa 3.4 ± 2.8 0.2
ICF −0.4 ± 0.8 0.6
LICI −0.5 ± 1.5 0.7
aOne or more subjects were not included in this model due to being influential observations according to Cook’s distance analysis. ADAS-Cog, cognitive subscale of the
Alzheimer’s Disease Assessment Scale; ICF, intracortical facilitation; LICI, long-interval intracortical inhibition; MEP, motor evoked potential; rMT/aMT, resting/active motor
threshold; rTMS, repetitive transcranial magnetic stimulation; SICI, short-interval intracortical inhibition; T5/T10/T30, Time-points at 5 10 and 30 min post intermittent
Theta Burst Stimulation.
normal subjects, which might have played a role for some
patients. And in an own study, we found that pharmacological
treatment can also have a specific impact on plasticity measures
in AD (Brem et al., 2013).
We also found reduced SICI and LICI in AD patients, which
were associated to baseline ADAS-Cog. LICI has been shown to
interact with short-latency afferent inhibition (SAI) in healthy
subjects (Udupa et al., 2009), which again has been shown to
be reduced in AD (Koch et al., 2012), and may be a valuable
biomarker that could be assessed in future studies using TMS-
EEG across regions of the cortical convexity (Farzan et al., 2010).
SICI has been previously reported to be reduced in AD patients
and to be related to disease severity (Liepert et al., 2001), however,
findings are divergent (Freitas et al., 2011). Atrophy over the
primary motor cortex was not associated with cortico-motor
reactivity and plasticity, and mean atrophy did not confound the
associations between cognitive and motor measures. Atrophy in
AD was significantly larger, specifically for the left IPL, which is
in accordance with previous findings stating that IPL is among
the first brain regions to show atrophy (Jacobs et al., 2011).
Clinical Effect
Overall training progression did not differ between the two
groups who received active cognitive training, indicating that
the addition of rTMS to cognitive training is crucial to achieve
cognitive improvements and not progression in the training.
High-frequency rTMS protocols (such as the 10 Hz stimulation
protocol used in the treatment phase of the present study)
are established as a safe and effective method to increase
brain excitability and have been applied in a wide range of
patient populations in a similar way as in the present study
(Bentwich et al., 2011; Cotelli et al., 2011; Chang et al., 2012;
Kakuda et al., 2013; Khedr et al., 2014; Yang et al., 2013;
Kim et al., 2014; Wobrock et al., 2015; McGirr et al., 2015;
Quan et al., 2015). The degree of improvement in the real/real
group is clinically meaningful (Schrag et al., 2012) and was not
mediated by potential effects of rTMS on depression. Previous
studies using the same approach (Bentwich et al., 2011; Rabey
et al., 2013; Lee et al., 2015; Rabey and Dobronevsky, 2016)
also reported similar changes in ADAS-Cog, which further
strengthens our findings. Interestingly, substantial cognitive
improvement occurred after the end of intervention, possibly
reflecting time-prolonged modulation of neurophysiological
processes underlying cognitive maintenance. After combining
the two sham groups, an improvement in the ADCS-CGIC in
the real intervention group that was associated with cognitive
improvement became significant, stressing the importance of the
addition of rTMS. Both the real/real and the real/sham group
improved significantly more in ADL than the sham/sham group
after the intervention.
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In contrast to previous studies (Bentwich et al., 2011; Rabey
et al., 2013; Lee et al., 2015; Rabey and Dobronevsky, 2016), we
used neuronavigation to ensure precise targeting of the desired
cortical brain regions. Furthermore, we demonstrated that sham
rTMS combined with real cognitive training (real/sham group)
showed similar effects as the sham/sham group, emphasizing
the importance of rTMS. Though, we cannot establish whether
rTMS in combination with cognitive training produces the
same effect as rTMS on its own, we strongly believe that
the combination is crucial (Brem and Sensi, 2018). Added
efficacy might arise from Hebbian mechanisms of synaptic
reinforcement induced by the combined impact of cognitive
training and rTMS on the same neural networks engaged in
the different tasks. This is supported by the demonstrated
cortico-motor reactivity and plasticity effects in the participants
studied in Boston. Blinding is difficult to assess given the
nature of this cohort. Nonetheless, when asked to indicate
group assignment among the participants studied in Boston,
6/10 patients (60%) in the real/real group and 6/11 patients
in the sham groups (55%) thought they had received real
intervention. However, as no electrical surface electrodes were
used in the sham protocol, we cannot entirely exclude non-
neural effects.
Our patients progressed less in training tasks related to the left
and right IPL the greater the cortical atrophy in these regions.
It is important to consider that greater atrophy would have
resulted in relatively lower rTMS intensity at cortical level in
IPL. Furthermore, training gains were significantly correlated
with absolute TMS intensity for the left DLPFC. Therefore,
considering that atrophy was a negative predictor of clinical
response, future studies may base stimulation intensity on the
modeling of current distribution (Wagner et al., 2008). Notably,
the activation of a broad range of brain areas known to be
associated with AD pathology was thought to maximize cognitive
effects. Though we did not find clear benefits of cognitive training
alone, we nevertheless observed numerical improvements across
a range of parameters. Optimizing and individualizing the
cognitive training could possibly improve interaction effects with
rTMS and enhance clinical outcomes.
Correlation of Physiological Measures
With Cognitive Performance Across
Treatment
Transcranial magnetic stimulation has been previously found to
be precise enough to track disease-related neuroplastic changes
of motor cortex output in early AD (Ferreri et al., 2003). Notably,
in our study, MEP amplitude, as well as plasticity at T5 and
T10, mean and maximum plasticity were all significant predictors
of clinical response, even when adjusting for mean atrophy
and other intervention parameters. Furthermore, the association
between ADAS-Cog and several plasticity measures, as well as
motor thresholds, was preserved across the intervention resulting
in significant cognitive improvement. Importantly, in the case of
plasticity measures, active rTMS intervention was a significant
modulator of this association. Thus, we found that measures
of iTBS-induced plasticity were associated to cognitive function
not only at baseline but also after intervention, in an rTMS-
dependent fashion.
During the intervention, rTMS was not applied to the motor
cortex, and yet this was the cortical area from which plasticity
measures were collected. The observed correlations between
cortico-motor plasticity and cognitive measures strongly suggest
that alterations in plasticity may occur globally. Further support
for this assumption is suggested by the positive correlation
found between maximum level achieved in training tasks and
stimulation intensity. A neuroimaging study has shown that
memory training can drive non-motor brain activation patterns
of patients with mild cognitive impairment toward normalization
(Belleville et al., 2011). Changes in motor cortical measures after
stimulation of non-motor areas have been reported previously
(Pallanti et al., 2012), as has prediction of non-motor effects
of prefrontal stimulation by motor cortical measures (Oliveira-
Maia et al., 2017). These effects could arise through changes
in overlapping subcortical glutamatergic and dopaminergic
pathways (Wang et al., 2012), which in turn could be driven via
cortico-subcortical projections from stimulated non-motor areas.
Study Limitations
This study did not assess the effects of rTMS alone, which would
have necessitated adding a fourth study arm. Though magnetic
stimulation alone could affect cognition without additionally
inducing brain activity (Wang et al., 2019), the combination
of rTMS with cognitive interventions is thought to be more
effective (Brem and Sensi, 2018). Given our main interest in the
combined method, we actively decided against using resources
for an additional study arm and to favor the inclusion of
two rTMS sham groups (2:1:1 randomization). The challenges
in enrolling AD patients in such an intensive protocol (daily
treatment for 6 weeks) account for the modest sample size.
Though the two study sites used slightly different criteria, we
believe that the effects of a center bias on the primary outcome are
minimal as results remained largely unchanged after adding the
results from Rome to the results from Boston (Supplementary
Results). However, the patients in Rome did not undergo
neurophysiological measures, which might have had an impact
on compliance, tiredness at pre- and posttest and likelihood to
adhere to the study plan. Finally, although we chose a control
cognitive task with minimal cognitive engagement in order to
avoid having the control condition represent an “uncontrolled
brain state,” it is possible that changes in brain state could
have lead to unspecific improvements in the sense of an active
control training.
CONCLUSION
We found that the combinatory treatment of rTMS and
cognitive training resulted in significant cognitive improvement
as assessed with the ADAS-Cog, while cognitive training alone
did not lead to significant improvement compared to placebo
treatment. Confirming prior reports, we show abnormalities in
the mechanisms of plasticity and cortical reactivity in patients
with AD, and show for the first time that these can be modulated
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by a combined non-invasive stimulation and cognitive training
paradigm resulting in behavioral, clinical and cognitive benefits.
This study supports the relevance of non-pharmacological
combinatory interventions in individuals with AD and provides
important groundwork for future studies to build upon. Many
questions remain to be answered, including how cognitive
improvements translate into patients’ daily lives and whether
neurophysiological measures could act as potential biomarkers
for interventions in AD. Future research should assess a broader
range of patients and aim to improve applicability in the
clinical environment.
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